AMPLITUDE is the first clinical trial to evaluate potential therapies for patients with mHSPC and known HRR gene alterations, with positive results supporting the niraparib-based combination regimen a ...
Tuko News on MSN
Fitch Ratings: Kenya's credit rating in 'junk' territory despite strong forex reserves
Fitch Ratings maintains Kenya's 'B-' credit rating with a Stable Outlook, highlighting fiscal challenges and governance risks ...
Rare earth stocks are surging as U.S. policy shifts and China asserts itself. Here are five rare-earth stocks poised to ...
Sagimet Biosciences dropped 9% after Ascletis Pharma’s Phase 3 Denifanstat safety data focused on tolerability, not new ...
Our sector weightings drove the portfolio’s performance, largely due to an underweight position relative to the benchmark in Treasuries and an overweight in securitized securities.
Onvansertib added to FOLFIRI/bev first-line standard of care regimen showed dose-dependent improvement in overall response rates and durability trends as measured by progression-free survival in patie ...
All bodily feelings reflect a sixth sense we have called interoception. Explore its interesting idiosyncrasies and the role ...
Saturday horse racing tips cheat sheet for ITV racing at Leopardstown, Musselburgh and Sandown plus Paul Nicholls exclusive runners preview ...
A presidential panel recommends freezing Nigeria rice imports, citing a surplus driven by high import volumes and falling ...
The Boeing Company (NYSE:BA) Q4 2025 Earnings Call Transcript January 27, 2026 The Boeing Company beats earnings expectations ...
Onvansertib added to FOLFIRI/bev first-line standard of care regimen showed dose-dependent improvement in overall response rates and durability trends as measured by progression-free survival in patie ...
Media ReleaseEntered into strategic collaboration with Dr. Reddy’s for commercialisation of eftilagimod alfa (efti) in all countries outside ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results